Cutaneous melanoma remains the most deadly form of skin cancer with a rapidly increasing global incidence.1 Oncogenic BRAF mutations, such as the common V600E substitution present in 30–50% of melanomas.2, 3 activate the downstream effector mitogen‐activated protein kinase kinase (MEK) to drive melanoma tumour growth. This evidence concerns the gene MAP2K7 and neoplasm.